Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,470,000 shares, an increase of 19.2% from the October 15th total of 2,910,000 shares. Approximately 6.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,150,000 shares, the short-interest ratio is currently 3.0 days.
Institutional Trading of Tempus AI
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its holdings in shares of Tempus AI by 0.4% in the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after purchasing an additional 539 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Tempus AI during the third quarter valued at about $502,000. Kovitz Investment Group Partners LLC purchased a new stake in shares of Tempus AI during the third quarter worth about $1,367,000. Stifel Financial Corp bought a new stake in shares of Tempus AI in the third quarter worth about $218,000. Finally, Benjamin Edwards Inc. purchased a new position in Tempus AI during the 3rd quarter valued at about $725,000.
Tempus AI Trading Down 7.5 %
Shares of NASDAQ TEM traded down $4.23 during midday trading on Friday, reaching $52.40. The company had a trading volume of 1,600,845 shares, compared to its average volume of 1,193,641. Tempus AI has a one year low of $22.89 and a one year high of $79.49. The company’s fifty day simple moving average is $51.25. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on TEM
Tempus AI Company Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Recommended Stories
- Five stocks we like better than Tempus AI
- Learn Technical Analysis Skills to Master the Stock Market
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- NYSE Stocks Give Investors a Variety of Quality Options
- Time to Load Up on Home Builders?
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.